Skip to main content

Early value dossiers for medical technologies

The essential tool to understand the value proposition for your product and position it well with reimbursement/HTA stakeholders

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

New project added to the Forfait Innovation program in France

21 Mar 2023

Forfait innovation is the most advanced coverage with the evidence development program in France. The program was initiated in 2015 and is only focused on medical devices, procedures and in-vitro diagnostic technologies. The objective of the Forfait Innovation program is to provide early support for breakthrough innovation and bridge serious evidence gaps simultaneously. The program includes a government co-sponsored study. The budget comes from three sources: the Ministry of Health (experimental arm), regular statutory health insurance (control arm), and an applicant (study infrastructure).

On March 8, 2023, the Ministry of Health and Prevention published an Order in the Official Journal of the French Republic on the coverage of the INTERVAPOR system under Forfait innovation program. The INTERVAPOR bronchoscopic system for reducing lung volume by water vapor in patients with severe heterogeneous emphysema of the upper lobe is included in Forfait innovation for a period of 40 months from the date of the first inclusion in the study. The amount of the flat-rate reimbursement, including reimbursement for the procedure and associated hospitalization costs, is set at €3,903 per patient. The total number of patients likely to benefit from reimbursement is set at 300, including 150 patients under the study and 150 additional patients not included in the study (during the follow-up phase).

See the details in French here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.